Department of Radiation Oncology, Shenzhen People's Hospital, The First Affiliated Hospital of Southern University of Science and Technology, Dongmenbei Road 1017, Shenzhen, 518000, Guangdong, People's Republic of China.
Center for AIDS/STD Control and Prevention, Sichuan Center for Disease Control and Prevention, Zhongxue Road 6, Chengdu, 610051, Sichuan, People's Republic of China.
Radiat Oncol. 2022 Jan 3;17(1):2. doi: 10.1186/s13014-021-01963-7.
Adjuvant radiotherapy following surgery reduces the local recurrence and improves the prognosis. However, a considerable part of patients developed digestive reaction in daily treatment. In order to explore the correlation between breast radiotherapy and gastric toxicity, we investigated the clinic symptoms and stomach dose during DIBH or FB mode while left-sided breast cancer patients (LSBCP) receiving radiotherapy.
In the study, 124 LSBCP received adjuvant radiotherapy after surgery at our department were analyzed clinical characteristics and enquired about gastrointestinal side effects after treatment. Moreover, dosimetric parameters were assessed.
There was no statistically significant difference between the two groups in age, T staging, N staging, hormone receptors, human epidermal receptor-2 (HER2), surgical methods, fractionated regimen, and chemotherapy conditions. However, larger stomach volumes and higher fractionated dose (Dmax/F) were associated with a statistically significantly greater risk for acute radiotherapy toxicity. In addition, the use of the DIBH gating technique (FB/DIBH) reduced the incidence of digestive reactions.
In order to cut down gastric side effects after breast radiotherapy, large meals should be avoided before treatment. DIBH treatment should be implemented in centers where conditions are satisfied to reduce radiotherapy side effects. Furthermore, dose limitation in stomach should be considered when the radiotherapy plan was formulated, especially for the patients treated with hypofractionated radiotherapy.
手术后辅助放疗可降低局部复发率并改善预后。然而,相当一部分患者在日常治疗中会出现消化道反应。为了探讨乳腺癌放疗与胃毒性之间的相关性,我们研究了接受放疗的左侧乳腺癌(LSBCP)患者在 DIBH 或 FB 模式下的临床症状和胃剂量。
在该研究中,我们分析了 124 例在我科接受手术后辅助放疗的 LSBCP 的临床特征,并在治疗后询问了胃肠道副作用。此外,还评估了剂量学参数。
两组在年龄、T 分期、N 分期、激素受体、人表皮生长因子受体-2(HER2)、手术方式、分割方案和化疗条件方面均无统计学差异。然而,较大的胃体积和较高的分割剂量(Dmax/F)与急性放疗毒性的风险显著增加相关。此外,使用 DIBH 门控技术(FB/DIBH)可降低消化道反应的发生率。
为了减少乳腺癌放疗后的胃部副作用,治疗前应避免大量进食。在条件满足的情况下,应在中心实施 DIBH 治疗,以减少放疗副作用。此外,在制定放疗计划时应考虑胃部剂量限制,特别是对于接受分次放疗的患者。